View ValuationNational Peroxide 将来の成長Future 基準チェック /06現在、 National Peroxideの成長と収益を予測するのに十分なアナリストの調査がありません。主要情報n/a収益成長率n/aEPS成長率Chemicals 収益成長19.4%収益成長率n/a将来の株主資本利益率n/aアナリストカバレッジNone最終更新日n/a今後の成長に関する最新情報更新なしすべての更新を表示Recent updatesValuation Update With 7 Day Price Move • May 08Investor sentiment improves as stock rises 43%After last week's 43% share price gain to ₹652, the stock trades at a trailing P/E ratio of 34x. Average trailing P/E is 23x in the Chemicals industry in India. Total returns to shareholders of 15% over the past year.Reported Earnings • May 05Full year 2026 earnings released: EPS: ₹19.20 (vs ₹3.91 loss in FY 2025)Full year 2026 results: EPS: ₹19.20 (up from ₹3.91 loss in FY 2025). Revenue: ₹2.96b (up 3.1% from FY 2025). Net income: ₹110.4m (up ₹132.8m from FY 2025). Profit margin: 3.7% (up from net loss in FY 2025). The move to profitability was primarily driven by higher revenue.New Risk • May 04New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 9.1% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Revenue has declined by 7.8% over the past year. Minor Risks Share price has been volatile over the past 3 months (9.1% average weekly change). Market cap is less than US$100m (₹3.15b market cap, or US$33.1m).お知らせ • Apr 29National Peroxide Limited to Report Q4, 2026 Results on Apr 30, 2026National Peroxide Limited announced that they will report Q4, 2026 results on Apr 30, 2026Board Change • Mar 31High number of new and inexperienced directorsThere are 6 new directors who have joined the board in the last 3 years. The company's board is composed of: 6 new directors. No experienced directors. No highly experienced directors. CEO & Director Rajiv Arora is the most experienced director on the board, commencing their role in 2023. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.Buy Or Sell Opportunity • Feb 24Now 21% undervalued after recent price dropOver the last 90 days, the stock has fallen 27% to ₹402. The fair value is estimated to be ₹506, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 7.8% over the last year. Meanwhile, the company became loss making.Reported Earnings • Feb 06Third quarter 2026 earnings released: EPS: ₹3.19 (vs ₹2.64 loss in 3Q 2025)Third quarter 2026 results: EPS: ₹3.19 (up from ₹2.64 loss in 3Q 2025). Revenue: ₹699.9m (up 13% from 3Q 2025). Net income: ₹18.3m (up ₹33.5m from 3Q 2025). Profit margin: 2.6% (up from net loss in 3Q 2025).お知らせ • Jan 22National Peroxide Limited to Report Q3, 2026 Results on Jan 28, 2026National Peroxide Limited announced that they will report Q3, 2026 results on Jan 28, 2026Reported Earnings • Nov 05Second quarter 2026 earnings released: EPS: ₹0.67 (vs ₹2.64 loss in 2Q 2025)Second quarter 2026 results: EPS: ₹0.67 (up from ₹2.64 loss in 2Q 2025). Revenue: ₹699.5m (up 13% from 2Q 2025). Net income: ₹3.86m (up ₹19.0m from 2Q 2025). Profit margin: 0.6% (up from net loss in 2Q 2025).お知らせ • Oct 29National Peroxide Limited to Report Q3, 2026 Results on Nov 03, 2025National Peroxide Limited announced that they will report Q3, 2026 results on Nov 03, 2025お知らせ • Jul 30National Peroxide Limited, Annual General Meeting, Sep 04, 2025National Peroxide Limited, Annual General Meeting, Sep 04, 2025, at 15:30 Indian Standard Time.Reported Earnings • Jul 30First quarter 2026 earnings released: EPS: ₹1.55 (vs ₹5.35 in 1Q 2025)First quarter 2026 results: EPS: ₹1.55 (down from ₹5.35 in 1Q 2025). Revenue: ₹686.8m (down 22% from 1Q 2025). Net income: ₹8.90m (down 71% from 1Q 2025). Profit margin: 1.3% (down from 3.5% in 1Q 2025). The decrease in margin was driven by lower revenue.お知らせ • Jul 24National Peroxide Limited to Report Q1, 2026 Results on Jul 29, 2025National Peroxide Limited announced that they will report Q1, 2026 results on Jul 29, 2025New Risk • Jun 18New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 7.9% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Revenue has declined by 14% over the past year. Minor Risks Less than 3 years of financial data is available. Share price has been volatile over the past 3 months (7.9% average weekly change). Market cap is less than US$100m (₹4.22b market cap, or US$48.8m).お知らせ • May 01National Peroxide Limited to Report Q4, 2025 Results on May 06, 2025National Peroxide Limited announced that they will report Q4, 2025 results on May 06, 2025お知らせ • Mar 19National Peroxide Limited Announces Resignation of Munish Bakshi as Vice President - Marketing & Sales, with Effect from April 11, 2025National Peroxide Limited informed that Mr. Munish Bakshi, Vice President - Marketing & Sales of the Company, has given a notice of resignation from the post of Vice President - Marketing & Sales to pursue another opportunity. Resignation: To pursue other career opportunity. Cessation is with effect from 11th April, 2025.お知らせ • Jan 17National Peroxide Limited to Report Q3, 2025 Results on Jan 23, 2025National Peroxide Limited announced that they will report Q3, 2025 results on Jan 23, 2025お知らせ • Oct 24National Peroxide Limited to Report Q2, 2025 Results on Oct 29, 2024National Peroxide Limited announced that they will report Q2, 2025 results on Oct 29, 2024お知らせ • Aug 02National Peroxide Limited Recommends Dividend for the Year Ended March 31, 2024National Peroxide Limited at its board meeting held on May 09, 2024 had recommended payment of dividend at 125%, that is INR 12.50 per Equity Share of INR 10 each for the year ended March 31, 2024 subject To Approve the Members in the upcoming Annual General Meeting of the Members to be held on August 27, 2024. Final Dividend if declared, will be paid within the timelines prescribed under the law. The Board of Directors at its meeting held on July 31, 2024, approved closure of Register of Members and Share Transfer Books of the Company from August 21, 2024 to August 27, 2024 (both days inclusive) for the purpose of AGM and determining names of members entitled to receive Dividend to be declared at the AGM. Hence, the record date for the AGM and final dividend is August 20, 2024.お知らせ • Aug 01National Peroxide Limited, Annual General Meeting, Aug 27, 2024National Peroxide Limited, Annual General Meeting, Aug 27, 2024.お知らせ • Jul 25National Peroxide Limited to Report Q1, 2025 Results on Jul 31, 2024National Peroxide Limited announced that they will report Q1, 2025 results on Jul 31, 2024 このセクションでは通常、投資家が会社の利益創出能力を理解する一助となるよう、プロのアナリストのコンセンサス予想に基づく収益と利益の成長予測を提示する。しかし、National Peroxide は十分な過去のデータを提供しておらず、アナリストの予測もないため、過去のデータを外挿したり、アナリストの予測を使用しても、その将来の収益を確実に算出することはできません。 シンプリー・ウォール・ストリートがカバーする企業の97%は過去の財務データを持っているため、これはかなり稀な状況です。 業績と収益の成長予測BSE:544205 - アナリストの将来予測と過去の財務データ ( )INR Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数3/31/20262,957110298342N/A12/31/20252,777-34N/AN/AN/A9/30/20252,708-67162157N/A6/30/20252,795-64N/AN/AN/A3/31/20252,869-22138187N/A12/31/20243,01273N/AN/AN/A3/31/20243,330168218364N/Aアナリストによる今後の成長予測収入対貯蓄率: 544205の予測収益成長が 貯蓄率 ( 6.9% ) を上回っているかどうかを判断するにはデータが不十分です。収益対市場: 544205の収益がIndian市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です高成長収益: 544205の収益が今後 3 年間で 大幅に 増加すると予想されるかどうかを判断するにはデータが不十分です。収益対市場: 544205の収益がIndian市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。高い収益成長: 544205の収益が年間20%よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。一株当たり利益成長率予想将来の株主資本利益率将来のROE: 544205の 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です成長企業の発掘7D1Y7D1Y7D1YMaterials 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/23 20:25終値2026/05/22 00:00収益2026/03/31年間収益2026/03/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋National Peroxide Limited 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
Valuation Update With 7 Day Price Move • May 08Investor sentiment improves as stock rises 43%After last week's 43% share price gain to ₹652, the stock trades at a trailing P/E ratio of 34x. Average trailing P/E is 23x in the Chemicals industry in India. Total returns to shareholders of 15% over the past year.
Reported Earnings • May 05Full year 2026 earnings released: EPS: ₹19.20 (vs ₹3.91 loss in FY 2025)Full year 2026 results: EPS: ₹19.20 (up from ₹3.91 loss in FY 2025). Revenue: ₹2.96b (up 3.1% from FY 2025). Net income: ₹110.4m (up ₹132.8m from FY 2025). Profit margin: 3.7% (up from net loss in FY 2025). The move to profitability was primarily driven by higher revenue.
New Risk • May 04New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 9.1% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Revenue has declined by 7.8% over the past year. Minor Risks Share price has been volatile over the past 3 months (9.1% average weekly change). Market cap is less than US$100m (₹3.15b market cap, or US$33.1m).
お知らせ • Apr 29National Peroxide Limited to Report Q4, 2026 Results on Apr 30, 2026National Peroxide Limited announced that they will report Q4, 2026 results on Apr 30, 2026
Board Change • Mar 31High number of new and inexperienced directorsThere are 6 new directors who have joined the board in the last 3 years. The company's board is composed of: 6 new directors. No experienced directors. No highly experienced directors. CEO & Director Rajiv Arora is the most experienced director on the board, commencing their role in 2023. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.
Buy Or Sell Opportunity • Feb 24Now 21% undervalued after recent price dropOver the last 90 days, the stock has fallen 27% to ₹402. The fair value is estimated to be ₹506, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 7.8% over the last year. Meanwhile, the company became loss making.
Reported Earnings • Feb 06Third quarter 2026 earnings released: EPS: ₹3.19 (vs ₹2.64 loss in 3Q 2025)Third quarter 2026 results: EPS: ₹3.19 (up from ₹2.64 loss in 3Q 2025). Revenue: ₹699.9m (up 13% from 3Q 2025). Net income: ₹18.3m (up ₹33.5m from 3Q 2025). Profit margin: 2.6% (up from net loss in 3Q 2025).
お知らせ • Jan 22National Peroxide Limited to Report Q3, 2026 Results on Jan 28, 2026National Peroxide Limited announced that they will report Q3, 2026 results on Jan 28, 2026
Reported Earnings • Nov 05Second quarter 2026 earnings released: EPS: ₹0.67 (vs ₹2.64 loss in 2Q 2025)Second quarter 2026 results: EPS: ₹0.67 (up from ₹2.64 loss in 2Q 2025). Revenue: ₹699.5m (up 13% from 2Q 2025). Net income: ₹3.86m (up ₹19.0m from 2Q 2025). Profit margin: 0.6% (up from net loss in 2Q 2025).
お知らせ • Oct 29National Peroxide Limited to Report Q3, 2026 Results on Nov 03, 2025National Peroxide Limited announced that they will report Q3, 2026 results on Nov 03, 2025
お知らせ • Jul 30National Peroxide Limited, Annual General Meeting, Sep 04, 2025National Peroxide Limited, Annual General Meeting, Sep 04, 2025, at 15:30 Indian Standard Time.
Reported Earnings • Jul 30First quarter 2026 earnings released: EPS: ₹1.55 (vs ₹5.35 in 1Q 2025)First quarter 2026 results: EPS: ₹1.55 (down from ₹5.35 in 1Q 2025). Revenue: ₹686.8m (down 22% from 1Q 2025). Net income: ₹8.90m (down 71% from 1Q 2025). Profit margin: 1.3% (down from 3.5% in 1Q 2025). The decrease in margin was driven by lower revenue.
お知らせ • Jul 24National Peroxide Limited to Report Q1, 2026 Results on Jul 29, 2025National Peroxide Limited announced that they will report Q1, 2026 results on Jul 29, 2025
New Risk • Jun 18New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 7.9% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Revenue has declined by 14% over the past year. Minor Risks Less than 3 years of financial data is available. Share price has been volatile over the past 3 months (7.9% average weekly change). Market cap is less than US$100m (₹4.22b market cap, or US$48.8m).
お知らせ • May 01National Peroxide Limited to Report Q4, 2025 Results on May 06, 2025National Peroxide Limited announced that they will report Q4, 2025 results on May 06, 2025
お知らせ • Mar 19National Peroxide Limited Announces Resignation of Munish Bakshi as Vice President - Marketing & Sales, with Effect from April 11, 2025National Peroxide Limited informed that Mr. Munish Bakshi, Vice President - Marketing & Sales of the Company, has given a notice of resignation from the post of Vice President - Marketing & Sales to pursue another opportunity. Resignation: To pursue other career opportunity. Cessation is with effect from 11th April, 2025.
お知らせ • Jan 17National Peroxide Limited to Report Q3, 2025 Results on Jan 23, 2025National Peroxide Limited announced that they will report Q3, 2025 results on Jan 23, 2025
お知らせ • Oct 24National Peroxide Limited to Report Q2, 2025 Results on Oct 29, 2024National Peroxide Limited announced that they will report Q2, 2025 results on Oct 29, 2024
お知らせ • Aug 02National Peroxide Limited Recommends Dividend for the Year Ended March 31, 2024National Peroxide Limited at its board meeting held on May 09, 2024 had recommended payment of dividend at 125%, that is INR 12.50 per Equity Share of INR 10 each for the year ended March 31, 2024 subject To Approve the Members in the upcoming Annual General Meeting of the Members to be held on August 27, 2024. Final Dividend if declared, will be paid within the timelines prescribed under the law. The Board of Directors at its meeting held on July 31, 2024, approved closure of Register of Members and Share Transfer Books of the Company from August 21, 2024 to August 27, 2024 (both days inclusive) for the purpose of AGM and determining names of members entitled to receive Dividend to be declared at the AGM. Hence, the record date for the AGM and final dividend is August 20, 2024.
お知らせ • Aug 01National Peroxide Limited, Annual General Meeting, Aug 27, 2024National Peroxide Limited, Annual General Meeting, Aug 27, 2024.
お知らせ • Jul 25National Peroxide Limited to Report Q1, 2025 Results on Jul 31, 2024National Peroxide Limited announced that they will report Q1, 2025 results on Jul 31, 2024